New drug cocktail aims to fight stomach cancer when first treatment fails
NCT ID NCT07139587
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has worsened or who could not tolerate first-line treatment. The goal is to see if this combination can shrink tumors and extend survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab/Tuvonralimab (immunotherapy) combined with albumin-bound paclitaxel (chemotherapy)
- What this could lead to
- If successful, this could offer a new second-line treatment option for advanced stomach cancer, potentially extending life and controlling the disease.
- What could go wrong
- This is a very small, early-phase trial with only 30 participants. The combination may not work better than existing options and could cause significant side effects from both immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei General Hospital
Shijiazhuang, Hebei, 050000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?